Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Decision Regarding Policy to File for Conditional and Time-Limited Approval of Ischemic Stroke Treatment in Japan and Development Strategy Overview
Completion of Formal Regulatory Consultation for ARDS and Agreement on the Global Phase 3 Trial (REVIVE-ARDS Study)
Selection for NEDO Public Call Project: 'Verification and Validation of Safety Toward Social Implementation of Japanese Medical-Specialized LLM'
Notice of Upcoming R&D Briefing on ARDS
Sarah Busch, PhD, appointed as CSO of Healios NA, Inc.
Announcement of Changes in Management
ONE-BRIDGE Trial in ARDS - Peer-Reviewed Publication in Japan
Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors
Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus
Notice of the Partial Amendments to Articles of Incorporation
FY2024 Financial Results (Material)
HEALIOS, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
HEALIOS, Last Fiscal Year's Undisclosed Net Income to Widen
The Conclusion of a Master Collaboration Agreement and License Option Agreement with Akatsuki Therapeutics Inc.
Launch of Medical Materials and Equipment Division
Agreement with AND medical to Supply Culture Supernatant
Announcement of Letter of Intent with Cell Resources for the Production of Culture Supernatant
Termination of Discussions with Nobelpharma regarding the Development and Commercializing Collaboration Agreement
Status of Conditional and Time-Limited Approval Application for ARDS in Japan (Clinical Part)
Promotion of Contract Manufacturing Business by ProcellCure